

**AGIMEXPHARM PHARMACEUTICAL  
JOINT STOCK COMPANY**

**THE SOCIALIST REPUBLIC OF VIETNAM**  
**Independence - Freedom - Happiness**

No.: 01/CBTT-AGP

*Long Xuyen City, January 8, 2025*

## **PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS**

To: Hanoi Stock Exchange

In compliance with Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020, issued by the Ministry of Finance, guiding the disclosure of information in the securities market, Agimexpharm Pharmaceutical Joint Stock Company submits the disclosure of its financial statements for the 4<sup>th</sup> quarter of 2024 to Hanoi Stock Exchange as follows:

### **1. Organization Name: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

- Securities symbol: AGP
- Address: 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
- Contact phone: 02963.856964
- Website: <http://agimexpharm.com>

### **2. Disclosure information content:**

- Fourth Quarter Financial Statements for the fiscal year ending December 31, 2024:

☒ Separate Financial Statements (The listed organization has no subsidiaries, and the superior accounting unit has no affiliated units);

☐ Consolidated Financial Statement (The listed organization has subsidiaries);

☐ Combined Financial Statement (The listed organization has affiliated units with separate accounting systems).

- Cases requiring explanation:

+ The auditor provided an opinion that is not a full acceptance of the Financial Statements (for the 2023 audited financial statements):

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

+ Profit after tax in the reporting period shows a deviation of 5% or more before and after the audit, or shifts from loss to profit or vice versa (for the 2023 audited financial statements):

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

+ Profit after tax in the income statement of the reporting period changes by 10% or more compared to the same period of the previous year:

☒ Yes

☐ No

Explanation document if applicable:

☒ Yes

☐ No

+ Profit after tax in the reporting period shifts from profit to loss compared to the same period of the previous year or vice versa:

☐ Yes

☒ No

Văn bản giải trình trong trường hợp tích có:

☐ Yes

☐ No

This information has been disclosed on the company's website on January 8, 2025 at the link:  
<https://agimexpharm.com/shareholder/?lang=en>


***Attachments:***

- Fourth Quarter Financial Statements for the fiscal year ending December 31, 2024;
- Explanation document.

**Organization Representative**

Legal Representative

**GENERAL DIRECTOR**



**PHAR. NGUYEN VAN KHA**